NASDAQ$PBYI
Puma Biotechnology Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Puma Biotechnology's financial performance for Q2 2023 was reported, featuring positive net income and cash flow.
Puma Biotechnology reported a net product revenue increase for Q2 2023 compared to Q2 2022. The company also achieved positive net income and cash flow during the quarter. They anticipate key milestones over the next 12 months, including initiating a Phase II clinical trial of alisertib in small cell lung cancer.
- Net product revenue increased to $51.6 million in Q2 2023, up from $51.3 million in Q2 2022.
- GAAP net income was $2.1 million, or $0.05 per basic and diluted share, compared to $9.4 million, or $0.21 per basic and diluted share, for the same period in 2022.
- Non-GAAP adjusted net income was $4.6 million, or $0.10 per basic and diluted share, compared to $12.6 million, or $0.28 per basic and diluted share, for the same period in 2022.
- Net cash provided by operating activities was $3.3 million, compared to net cash used in operating activities of $13.9 million for the same period in 2022.
Headline financials
Revenue & EPS history
Puma Biotechnology · Revenue · Quarterly
$54.6M
Revenue by segment
Puma Biotechnology · $56.1M total across 2 segments · Q3 2023
- Product Revenue, Net$51.6M—92.0%
- Royalty Revenue$4.5M+60.7%8.0%
Forward guidance
Puma Biotechnology provided financial outlook for the third quarter and full year 2023.
Tailwinds
- Third quarter product revenue, net is expected to be between $51 million and $53 million.
- Third quarter royalty revenue is expected to be between $3 million and $5 million.
- Third quarter net income is expected to be between $3 million and $4 million.
- Full year 2023 product revenue, net is expected to be between $205 million and $210 million.
- Full year 2023 royalty revenue is expected to be between $25 million and $30 million.
Headwinds
- Full year 2023 gross to net adjustment is expected to be between 19% and 20%.
- Third quarter gross to net adjustment is expected to be between 17.5% and 18.5%.
- Full year 2023 net income is expected to be between $20 million and $24 million.
- Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
- These statements are based on current expectations, forecasts and assumptions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-1.6%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+4.4%
Avg return
30 days after
47%
21 / 45 earnings
Positive
+36.4%
Q4 2018
Best reaction
-45.8%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -6.0% | -5.8% | |
| Q4 2025 | -25.1% | -15.8% | -20.0% | |
| Q3 2025 | +21.8% | +1.8% | +8.2% | |
| Q1 2025 | -4.6% | -5.5% | +21.2% | |
| Q4 2024 | +19.7% | +18.4% | +5.0% | |
| Q3 2024 | -5.9% | +4.9% | +2.0% | |
| Q2 2024 | +6.7% | +12.3% | -30.4% | |
| Q1 2024 | -1.8% | -4.0% | -22.2% | |
| Q4 2023 | -10.8% | -21.5% | -19.7% | |
| Q3 2023 | +4.9% | +9.4% | +41.5% | |
| Q2 2023 | +5.8% | +13.3% | +2.5% | |
| Q1 2023 | +19.8% | +19.4% | +35.0% | |
| Q4 2022 | -20.1% | -26.6% | -23.1% | |
| Q3 2022 | +25.5% | +50.9% | +106.0% | |
| Q2 2022 | +23.5% | +17.4% | -17.0% | |
| Q1 2022 | -19.1% | -26.0% | -4.9% | |
| Q4 2021 | +13.5% | +25.7% | +34.2% | |
| Q3 2021 | -39.1% | -42.2% | -54.6% | |
| Q2 2021 | +3.6% | +3.6% | +7.9% | |
| Q1 2021 | +1.6% | -0.8% | +17.0% | |
| Q4 2020 | -11.9% | -11.9% | -12.6% | |
| Q3 2020 | -11.0% | +1.3% | +31.8% | |
| Q2 2020 | -5.7% | -7.9% | -11.6% | |
| Q1 2020 | +11.2% | +23.1% | +6.4% | |
| Q4 2019 | -2.4% | -18.8% | -43.9% | |
| Q3 2019 | +4.2% | +18.0% | +9.1% | |
| Q2 2019 | +26.7% | +25.8% | +22.1% | |
| Q1 2019 | -38.6% | -41.5% | -53.9% | |
| Q4 2018 | +36.4% | +35.3% | +35.9% | |
| Q3 2018 | -45.8% | -39.5% | -37.3% | |
| Q2 2018 | -7.5% | -7.1% | -2.1% | |
| Q1 2018 | -19.0% | -18.9% | -24.3% | |
| Q4 2017 | +8.7% | +16.7% | +4.1% | |
| Q3 2017 | -22.2% | -24.3% | -23.9% | |
| Q2 2017 | -11.6% | -1.7% | +28.0% | |
| Q1 2017 | +1.5% | +4.3% | +163.9% | |
| Q4 2016 | -10.6% | -8.3% | +1.4% | |
| Q3 2016 | +21.3% | -0.5% | -9.4% | |
| Q3 2015 | -9.6% | — | — | |
| Q1 2015 | +2.0% | — | — | |
| Q4 2014 | -3.3% | — | — | |
| Q1 2013 | +3.7% | — | — | |
| Q3 2012 | -6.4% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +1.9% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro